GlassScriptPhysician profile
Vikranth Reddy Gongidi
NPI 1609098581
$9,014.65
in general payments reported to CMS, 2019-2025
27 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,306 · 2021: $262 · 2022: $366 · 2023: $757 · 2024: $2,765 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,586 · Travel and Lodging: $1,396 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,585.52 |
| Travel and Lodging | $1,396.28 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $2,187.43 | 2019 | |
| Medtronic, INC. | $1,926.07 | 2021-2024 | Linq II, Micra, Reveal Linq |
| Abbott Laboratories | $1,724.16 | 2019-2025 | Amplatzer Amulet, Mitraclip, Pressurewire |
| Boston Scientific Corporation | $377.49 | 2022-2025 | Watchman Access System, Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| E.R. Squibb & Sons, L.L.C. | $268.73 | 2022-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $264.05 | 2025 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $239.04 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $227.05 | 2022-2025 | |
| United Therapeutics Corporation | $217.40 | 2024-2025 | Orenitram, Tyvaso, Remodulin |
| Alnylam Pharmaceuticals INC. | $210.90 | 2024-2025 | Amvuttra, Onpattro |
| Cvrx, INC. | $206.07 | 2025 | Barostim Neo System |
| Atricure, INC. | $178.93 | 2024-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Bridgebio Pharma, INC. | $150.45 | 2025 | Attruby |
| Edwards Lifesciences Corporation | $138.57 | 2023 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $110.19 | 2022-2025 | Verquvo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $92.94 | 2023-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.79 | 2023-2025 | Jardiance |
| Pfizer INC. | $77.58 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $74.32 | 2021-2024 | Farxiga, Wainua |
| Lexicon Pharmaceuticals, INC. | $70.66 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $63.57 | 2019-2024 | Lifevest |
| Bracco Diagnostics INC. | $37.83 | 2022 | |
| Glaxosmithkline, LLC. | $19.55 | 2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $17.25 | 2025 | Zepbound |
| Novo Nordisk INC | $17.23 | 2024 | Ozempic |
| Janssen Pharmaceuticals, INC | $17.04 | 2024 | Xarelto |
| Scpharmaceuticals INC. | $13.36 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikranth Gongidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.